Prevalence of Cardiovascular and Cancer Risk Factors Among Rheumatoid Arthritis Patients Prescribed JAK Inhibitors and Tumor Necrosis Factor Inhibitors: A Cross‐Sectional Study
Authors' conclusion
In recent years, JAKi and TNFi were used in similar proportions to treat RA among commercially-insured patients at elevated cardiovascular and cancer risk.
Study context
- Population
- Commercially-insured patients with rheumatoid arthritis (RA), August 16, 2019 to March 31, 2022, continuously eligible 12 months before index date
- Participants
- 12,673 patients
- Exposure
- Tumor necrosis factor inhibitors (TNFi) vs JAK inhibitors (JAKi), first dispensed treatment
- TNFin = 7,748reference
- JAKin = 4,925
- Outcome
- Prevalence of elevated cardiovascular and cancer risk (age ≥65 years, smoking, or history of MACE, VTE or cancer)
- Follow-up
- Baseline (12 months before index date)
Methodological detailsclaims database (Merative MarketScan Commercial and Medicare)
- Claims database (Merative MarketScan Commercial and Medicare)
Main finding
As reported in the abstract
Prevalence of elevated risk
Observational data: associations, not effects.
Further findings
≥1 primary modifiable risk factor, elevated vs low risk, JAKi (subgroup)
PD 21% (18%–24%)
≥1 primary modifiable risk factor, elevated vs low risk, TNFi (subgroup)
PD 21% (19%–23%)
Original publication
Prevalence of Cardiovascular and Cancer Risk Factors Among Rheumatoid Arthritis Patients Prescribed JAK Inhibitors and Tumor Necrosis Factor Inhibitors: A Cross‐Sectional Study. Arthritis Care Res (Hoboken). Published 21 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →